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1. Introduction 
Atherosclerosis, with its dramatic events, represents a heavy burden in terms of morbidity 
and mortality throughout the entire world (Gibbons et al., 2008). Although the risk factors 
are very well known and addressed by every physician (genetic background, physical 
inactivity, hypertension, dyslipidemia, diabetes mellitus, obesity and metabolic syndrome, 
smoking), the precise mechanisms of the plaque formation and rupture are not completely 
clarified.  These limitations are confirmed by the difficulties in obtaining better results in 
both primary and secondary prevention of cardiovascular events: recent results of 
completed clinical trials (such as NAVIGATOR, ACCORD, ROADMAP) suggest that we 
have reached a limit in terms of reducing events by simply addressing common risk factors 
appropriately (Zanchetti, 2009). As a matter of fact, at the present time we cannot prevent 
70% of clinical events, also with administration of all well established anti-atherosclerotic 
therapeutics. In addition at least 10% of coronary events can occur in apparently healthy 
subjects in the absence of traditional risk factors (Baigent et al., 2005; Greenland et al., 2003). 
The inflammatory paradigm has represented an important achievement in the 
understanding of the atherosclerotic process: abundant laboratory and clinical evidence 
accumulated over the last twenty years, also from our research group (Montecucco et al. 
2010), confirming the hypothesis that inflammation exerts a major role through the different 
stages of atherosclerosis (Ross, 1999; Hansson, 2005; Hansson & Libby, 2006; Libby et al., 
2009). Therefore it would be interesting to evaluate how the therapeutic choices exerted by 
physicians can modulate the inflammatory activation (the so called pleiotropic effects): in 
other terms do the drugs we use in the attempt of counteracting atherosclerosis (such as 
anti-hypertensive drugs, statins, fibrates, aspirin, anti-diabetic drugs) exert their protective 
effects through their main site of action (decrease of blood pressure, cholesterol, 
triglycerides, and glucose, anti-platelets actions) or can an additional anti-inflammatory 
effect be proposed, at least for some of them? This is the reason why recently Ridker 
proposed a clinical trial with low-dose methotrexate, a powerful anti-inflammatory drug 
extensively used in the treatment of auto-immune disease (suc as rheumatoid arthritis), in 
post-myocardial infarction (MI) patients (Ridker, 2009); another testable drug could be 
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canakinumab, a human monoclonal antibody targeted against interleukin-1 (Libby et al., 
2011).  
In theory these approaches have a great appeal because their main target is represented by 
the basic mechanism of the atherosclerotic process, i.e. the inflammatory activation,  but the 
risk of untoward effects can overcome the expected benefits: particularly in primary 
prevention the possible depression of the immune system and defense against cancer may 
be too dangerous in a substantially healthy population. In addition the involvement of the 
immune system, and consequently the inflammatory activation, is not completely elucidated 
because the entire network is particularly complex with many pathways, both redundant 
and with opposite effects, and many cells (Libby et al., 2011). Another reason for our 
difficulties is represented by the realization of the incomplete concordance between 
atherosclerosis in human vessels and the possible animal models (Bentzon & Falk, 2010): the 
hypotheses generated by the experimental research frequently do not find a confirmation in 
a clinical scenario.         
The road of the anti-inflammatory approach in the treatment of atherosclerosis is paved by 
many defeats: table 1 tries to summarize the possible explanations. 
  
Possible explanations Example 
Important side effects NSAIDs, Corticosteroids, Torcetrapib 
Activation of dangerous pathways COX-2 inhibitors 
Secondary target Fibrates 
Unfavourable effects on lipid profile Rosiglitazone 
Marked differences in vitro vs. in vivo conditions Anti-oxidant agents 
Too late and too shy treatment  All the possible options? 
Table 1. Possible reasons of negative or partly successful trials for atherosclerosis  
A new and theoretically safer way to modulate the inflammatory activation could involve 
new lipid anti-inflammatory mediators, such as lipoxins, resolvins, protectins, and maresins: 
these molecules derive from the transformation of both the ω-6 fatty acid arachidonic acid 
and the ω-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid via actions of 
lipoxygenase, cyclooxygenase-2 and aspirin-acetylated COX-2 enzymes (Hersberger, 2010; 
Maskrey et al., 2011). These mediators exert significant effects favoring the resolution of the 
inflammatory process through the activation of a specific program, characterized by 
apoptosis and subsequent clearance of inflammatory cells. Again anti-inflammatory 
mediators are tightly linked, in terms of chemical structure and synthetic pathways, to pro-
inflammatory molecules, such as leukotrienes. At the present time, among available drugs, 
aspirin and statins seem to be able to activate these pathways significantly (Spite & Serhan, 
2010): the theoretical advantage would be represented by targeting inflammation without 
precipitating sustained immunosuppression.        
Another important preliminary consideration is  related to the ongoing debate about the 
appropriate timing of the beginning in anti-atherosclerotic treatments (Steinberg, 2010; 
Pletcher & Hulley, 2010). Although we need to never forget the fundamental role of healthy 
lifestyle choices, we know that some people are at potential high risk of vascular damage 
and consequently in this subset a more aggressive pharmacological approach can be 
advisable. The two opposite points of view are represented by physicians who support an 
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aggressive therapy (at least with statins and antihypertensives, when indicated) at young 
age, i.e. at the beginning of the atherosclerotic process, and physicians who underline the 
risk of the creation of a “pseudodisease” (Lauer, 2011).     
Directly linked to this topic is the role of biomarkers and vascular imaging in supporting 
treatment decisions: if we identify subclinical markers of atherosclerotic damage, we can use 
them in the prognostic stratification and consequently in rational therapeutic strategies. This 
consideration is an implicit criticism to the Framingham Risk Score (and other related risk 
calculators), a simple, relatively inexpensive, and useful way to predict cardiovascular 
events in the general population (Shah, 2010; Forrester, 2010). Limitations of the 
Framingham Risk Score include a substantial underestimation of lifetime risk and 
misclassification of some subgroups of subjects; in addition it does not incorporate family 
history and some components of the metabolic syndrome, important risk factors for 
coronary heart disease, and more importantly does not take into consideration the possible 
help of the noninvasive detection of subclinical atherosclerosis. Therefore we can reasonably 
affirm that Framingham Risk Score is very useful at the population level, but it remains 
suboptimal for individual subjects. 
Subclinical atherosclerosis always begins with fatty streak lesions, which are already 
extensively diffuse by 30 years of age (Shah, 2010; Lauer, 2010): although we know that fatty 
streaks are reversible, we are also aware that this lesion is certainly the precursor of the 
stenotic plaque. Do we have validated imaging tools for subclinical atherosclerosis? 
Essentially, we can rely on coronary calcium score, obtained by computed tomography 
without contrast, and on carotid intima-media thickness, evaluated by B-mode 
ultrasonography (US). With some limitations (Shah, 2010; U.S. Preventive Services Task Force, 
2009) they represent a useful aid in better classification of risk categories in human subjects: 
some years ago the SHAPE (Screening for Heart Attack Prevention and Education) Task Force 
recommended noninvasive atherosclerosis imaging of all asymptomatic men (age 45 – 75 
years) and women (age 55 – 75 years), except those at very low risk, to augment conventional 
cardiovascular risk assessment algorithms (Naghavi et al., 2006): recently these guidelines 
were positively evaluated in the Dallas Heart Study, with significant bidirectional 
reclassification of eligibility for lipid-lowering therapy in the participants (See et al., 2008). 
About serum biomarkers the role of high-sensitivity C-reactive protein (hsCRP) is well 
established and will be evaluated in depth for statins. Recently 30 biomarkers for 
atherosclerosis, or more in general cardiovascular diseases, were studied in two large 
cohorts totalling more than 9,000 subjects (Blankenberg et al., 2010): a consistent association 
with incident cardiovascular events was observed for hsCRP, B-type natriuretic peptide and 
cardiac troponin I. These observations allowed the development of a biomarker score which 
was positively validated in a cohort of male subjects.              
The present article will present updated information about the anti-inflammatory effects of 
different classes of drugs and the possible therapeutic advantages obtained with this 
approach. Before starting the evaluation we need to never forget the fundamental protective 
role exerted by a healthy lifestyle: very recently we extensively reviewed these choices and 
their great social value (Pende & Dallegri, 2011). However we know that their 
implementation and long-term compliance is very low: a possible help is  the potentiation of 
population-based strategies, such as smoking bans and food legislation against trans-fats 
and high amount of salt.   
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Table 2 gives some information about the clinical trials discussed in the review with full 
definition of the names. 
 
Clinical trial acronym Clinical trial name Drugs tested 
ACCORD-Lipid  Action to Control Cardiovascular Risk in 
Diabetes 
Simvastatin, fenofibrate 
AFCAPS/TexCAPS Air Force/Texas Coronary Atherosclerosis 
Prevention Study  
Statins 
ARBITER 6-HALTS Arterial Biology for the Investigation of the 
Treatment Effects of Reducing Cholesterol 6 - 
HDL and LDL Treatment Strategies in 
Atherosclerosis 
Ezetimibe, niacin 
ARIC Atherosclerosis Risk in Communities Multiple drugs 
ARISE Aggressive Reduction of Inflammation Stops 
Events 
Succinobucol 
A-to-Z Aggrastat to Zocor Simvastatin 
CAMELOT Comparison of Amlodipine vs Enalapril to 
Limit Occurrences of Thrombosis 
Amlodipine, enalapril 
CARE Cholesterol and Recurrent Events Pravastatin 
DEFINE Determining the Efficacy and Tolerability of 
CETP Inhibition with Anacetrapib. 
Anacetrapib 
HPS2-THRIVE Treatment of High density lipoprotein to 
Reduce the Incidence of Vascular Events 
Niacin/laropiprant 
ILLUMINATE Investigation of Lipid Level Management to 
Understand its Impact in Atherosclerotic 
Events 
Torcetrapib 
JUPITER Justification for the Use of Statin in 
Prevention: an Intervention Trial Evaluating 
Rosuvastatin 
Rosuvastatin 
MIRACL Myocardial Ischemia Reduction with 
Aggressive Cholesterol Lowering 
Atorvastatin 
NAVIGATOR Nateglinide and Valsartan in Impaired 
Glucose Tolerance Outcomes Research 
Nateglinide, valsartan 
PLASMA Phospholipase Levels And Serological 
Markers of Atherosclerosis 
Varepladib 
PROactive Prospective Pioglitazone Clinical Trial in 
Macrovascular Events 
Pioglitazone 
PROVE IT-TIMI 22 Pravastatin or Atorvastatin Evaluation and 
Infection Therapy Thrombolysis in 
Myocardial Infarction 22  
Pravastatin, atorvastatin 
REVERSAL Reversing Atherosclerosis with Aggressive 
Lipid Lowering 
Pravastatin, atorvastatin 
ROADMAP Randomised Olmesartan and Diabetes 
Microalbuminuria Prevention 
Olmesartan 
SOLID-TIMI 52 Stabilization of Plaques Using Darapladib —
Thrombolysis in Myocardial Infarction 52 
Darapladib 
STABILITY Stabilization of Atherosclerotic Plaque by 
Initiation of Darapladib Therapy  
Darapladib 
VISTA-16 Vascular Inflammation Suppression to Treat 
Acute Coronary Syndrome for 16 Weeks 
Varespladib 
Table 2. Acronyms of clinical trials discussed in this review 
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2. HMG-CoA reductase inhibitors (statins) 
Although the main mechanism of action of this class of drugs is the inhibition of the 
cholesterol synthesis, since the end of the last century a significant anti-inflammatory effect 
appeared to be present as additional explanation of the results in randomized controlled 
trials. The specific biomarker for inflammation was CRP and this molecule maintained its 
role in many different trials until present time.  
Although the association between CRP and coronary artery disease was first observed more 
than two decades ago (Berk et al., 1990), researchers are still debating  about the precise 
position of CRP in clinical and experimental atherosclerosis (Ridker, 2007; Schunkert & 
Samani, 2008; Casas et al., 2008; Nordestgaard, 2009; Anand & Yusuf, 2010; Boekholdt & 
Kastelein, 2010; Després, 2011; Keavney, 2011): some authors think that CRP exerts a 
fundamental role in the beginning of the vascular inflammatory process (for example 
through the activation of the classical complement pathway and enhancement of the innate 
immune response), instead a more conservative opinion regards CRP no more than a useful 
but unspecific biomarker of inflammation (an innocent bystander). In practical terms, its 
long half-life (about 19 h), its limited cost and possibility of replication of the assay in the 
follow-up without health issues for the patients represent good features. In addition CRP 
seems to meet most of the American Heart Association (AHA) statement criteria for use of a 
novel cardiovascular risk marker (proof of concept, prospective validation, incremental 
value beyond other risk factors, and clinical utility) (Hlatky et al., 2009). For these reasons 
Ridker et al. proposed and validated a new clinical risk algorithm, Reynolds risk score for 
both women (Ridker at al., 2007) and men (Ridker et al., 2008a), which incorporates 
information on both inflammation (hsCRP) and genetics (parental history of premature MI). 
The utility of hsCRP for risk reclassification was confirmed also in the Framingham Heart 
Study (Wilson et al., 2008).      
Statins can exert their anti-inflammatory role through different effects: the combined actions 
are called pleiotropic effects and are abundantly reviewed in the literature (C.Y. Wang et al., 
2007; Ludman et al., 2009). The main mechanism seems to be always related to the inhibition 
of HMG-CoA reductase enzyme, involved in the rate-limiting step in cholesterol 
biosynthesis, but also in the production of isoprenoid intermediates, such as farnesyl-
pyrophosphate and geranyl-geranyl-pyrophosphate: these molecules are important for the 
post-translational modification of small GTP-binding proteins Ras, Rac, and Rho, which are 
known to modulate vascular smooth muscle cell proliferation, platelet aggregation, and 
plaque stability.       
Returning to statin trials, CARE study of secondary prevention was able to demonstrate, in 
a post hoc analysis, that pravastatin decreased CRP levels significantly in comparison to 
placebo; this decrease did not correlate with the reduction in cholesterol levels (Ridker et al., 
1999). Few years later similar results were obtained in a primary prevention study, the 
AFCAPS/TexCAPS trial (Ridker et al., 2001): an interesting observation was the absence of 
clinical benefits in subjects with low density lipoprotein (LDL)-cholesterol <150 mg/dl and 
hsCRP levels <2 mg/l, instead a significant benefit was found in those with LDL-cholesterol 
levels <150 mg/dl and hsCRP >2 mg/l. Further studies, such as MIRACL (Kinlay et al., 
2003), REVERSAL (Nissen et al., 2005), A to Z (Morrow et al., 2006), and PROVE IT-TIMI 
22(Ridker et al., 2005), demonstrated effects of statins on CRP. Again in all these studies the 
statin-induced reductions of CRP and LDL-cholesterol levels were only weakly correlated, 
www.intechopen.com
 
Cardiovascular Risk Factors 
 
306 
whereas the decrease in CRP was correlated with slowed atherosclerosis progression, in an 
independent way with respect to LDL-cholesterol decrease. In PROVE IT-TIMI 22 and in A 
to Z trials the best outcomes were observed in individuals who reached both LDL-
cholesterol levels <70 mg/dl and hsCRP <2.0 mg/l. Therefore the concept of a “dual target” 
for statin therapy (LDL-cholesterol and CRP) was introduced.  
A step forward was represented by the JUPITER trial (Ridker et al., 2008b). JUPITER was a 
large, double-blind, placebo-controlled trial, multinational, primary prevention trial, which 
recruited 17,802 apparently healthy subjects with entry criteria of less than 130 mg/dl for 
LDL-cholesterol levels and hs-CRP levels of 2.0 mg/dl or higher. Subjects were randomly 
assigned to 20 mg/d of rosuvastatin or placebo and continued their usual standard care; the 
primary end point was a combination of MI, stroke, arterial revascularization, 
hospitalization for unstable angina, or death from cardiovascular causes. 
The trial was terminated prematurely, after a mean of only 1.9 years of follow-up by an 
indipendent data and safety monitoring board. The absolute risk reduction was 1.2%, with 
the primary endpoint occurring in 2.8% of subjects in the placebo arm versus 1.6% of 
subjects in the rosuvastatin arm. The active treatment reduced the risk for first MI by 55%, 
the risk for venous thromboembolism by 52%, the need for coronary artery bypass grafting 
(CABG) or percutaneous coronary intervention (PCI) by 47%, and total mortality by 20%. 
On the basis of the Kaplan-Meier estimates and with a forward projection of the results, 
about 25 subjects would have to be treated for 5 years to prevent one primary endpoint. This 
estimate is very favourable, compared to trials evaluating statins in hyperlipidemic patients, 
where the 5-year number needed to treat patients was between 44 and 65; more strikingly in 
hypertension treatment the 5-year number needed to treat patients ranged between 86 and 
140. The treatment with rosuvastatin was well tolerated even at very low attained levels of 
LDL-cholesterol (less than 50 mg/dl) with consequent lower risk of cardiovascular events 
(Hsia et al., 2011). Moreover the study demonstrated a 43% reduction in venous thrombosis. 
Another limited but important finding was the increase in the rate of diabetes mellitus as 
well as a small, significant increase in the median value of glycated hemoglobin: this 
observation was confirmed in a recent meta-analysis of 13 statin trials which showed a 9% 
increased risk of development of diabetes associated with statin therapy (Sattar et al., 2010).  
The publication of the JUPITER trial spurred intense debate, sometimes with harsh 
criticisms to the authors (de Lorgeril et al., 2010; Kaul et al., 2010): the main points were the 
too early termination (with possible overestimation of the results), unprecise definitions of 
the endpoints (in particular about mortality), the undertreatment for the usual care of the 
involved patients, the increased health costs of this preventive approach, the excessive role 
of the pharmaceutical company. The trial however survived to the critics and convinced the 
United States Food and Drug Administration to approve the indication of rosuvastatin for 
reduction of acute MI, stroke, CABG, and PCI in men >50 years of age and women >60 years 
of age with hsCRP levels 2 mg/l who also have 1 additional cardiovascular risk factor. In 
addition in 2009 Canadian Cardiovascular Society guidelines included the results of the 
JUPITER trial recommending that also subjects at intermediate risk, defined as 10 – 20% risk 
at 10 years by Framingham criteria, should be treated with a statin when hsCRP is >2 mg/l. 
JUPITER conclusions were similar to the results subsequently obtained in the ARIC study 
(Yang et al., 2009), again showing that, starting with individuals at highest risk, the relative 
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cardiovascular event rates are high LDL-cholesterol + high CRP > high CRP + low LDL-
cholesterol > high LDL-cholesterol + low CRP > low LDL-cholesterol + low CRP. 
Another cholesterol-lowering drug, frequently administered with a statin, is ezetimibe, an 
inhibitor of the intestinal cholesterol transporter Niemann-Pick C1-like protein (NPC1L1): 
this drug can reduce LDL-cholesterol levels by almost 20% in individuals already taking a 
statin. However no clinical trial results have so far demonstrated that this combination will 
reduce cardiovascular events in comparison with statins only. In terms of anti-inflammatory 
effects ezetimibe per se did not reduce CRP levels, but it was able to help statin in 
decreasing CRP more deeply (Al Badarin et al., 2009). 
3. High Density Lipoprotein (HDL)-modulating agents 
Main focus of anti-atherosclerotic therapy is correctly the decrease in LDL-cholesterol levels. 
Although the success in terms of cardiovascular prevention was outstanding, we know that 
it is limited: as already stated, no more than 25-30% relative risk reduction was observed in 
statin monotherapy trials with a large amount of individuals in the active arm still suffering 
a cardiovascular event. This can be related to the different levels attained for LDL-
cholesterol in the trials with progressive updates of the international guidelines for 
atherosclerosis with the motto “lower for LDL-cholesterol is always better” (Grundy, 2008), 
but undoubtedly a residual risk is still present: “lower LDL-cholesterol is better but it is not 
enough” (Superko & King III, 2008).  
Another related observation, based on arteriographic findings, is the positive significant 
effect of statins on the decrease in the rate of atherosclerotic progression but the absent effect 
on any regression, something demonstrated on the contrary with a combined treatment 
(LDL-cholesterol reduction + HDL-cholesterol increase) (Superko & King III, 2008). This was 
confirmed recently by the conclusions of the ARBITER 6-Halts study which compared the 
effects of ezetimibe, an inhibitor of cholesterol absorption, and extended-release niacin in 
high risk patients already with statin therapy: the primary end point was the change in the 
intima-media thickness of common carotid artery (Taylor et al., 2009). Niacin was 
significantly superior to ezetimibe in the primary end point, suggesting again that the 
addition of a HDL-cholesterol raising drug to a statin is superior to a further LDL-
cholesterol decreasing strategy.        
Although a recent meta-analysis has suggested that increasing HDL-cholesterol does not 
reduce the risk of cardiovascular events in human subjects (Briel et al., 2009), animal studies 
have provided strong evidence that HDL-cholesterol is protective (Haas & Mooradian, 
2011). HDL exerts a key role in the reverse cholesterol transport, whereby cholesterol is 
transported from peripheral cells to the liver and consequently fostering the removal of this 
molecule from the lipid-laden macrophages at the vascular level. In addition HDL particles 
have been shown to be involved in direct anti-oxidative, anti-apoptotic, anti-thrombotic, and 
also anti-inflammatory functions (Tabet & Rye, 2009), suggesting further protection against 
the atherosclerotic process. However we need to be aware that, during the inflammatory 
activation, HDL particles can shift to a “dysfunctional” setting, showing on the contrary 
pro-inflammatory properties (Säemann et al., 2010): therefore the functional properties of 
HDL reflect its role more appropriately than mere serum concentrations.  
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At the present time, among HDL-cholesterol-increasing drugs, niacin (nicotinic acid) is the 
most effective agent, raising HDL-cholesterol by 20-30% (Farmer, 2009) with an important 
side effect (flushing), which can be attenuated by both an extended-release formulation 
(Knopp et al., 1998) and a combination with a prostaglandin D2 receptor 1 antagonist, 
laropiprant (Perry, 2009). The results of the HPS2-THRIVE ongoing study will give us 
important information about the therapeutic role of this combination in the prevention of 
cardiovascular events. In the meantime we already know that niacin exerts direct anti-
inflammatory effects, in particular an anti-oxidant and a CRP-decreasing activity (Sanyal et 
al., 2007; Thoenes et al., 2007).  
The most effective way to increase HDL-cholesterol was thought to be the inhibition of the 
cholesteryl ester transfer protein (CETP), the enzyme responsible for the transfer of 
cholesteryl esters from HDL particles to very low-density lipoproteins and LDLs (Barter & 
Kastelein, 2006). The first developed CETP-inhibitor was torcetrapib, which was evaluated 
in the ILLUMINATE trial (Barter et al., 2007): in this study patients at high cardiovascular 
risk were randomly assigned to receive either torcetrapib + atorvastatin or placebo + 
atorvastatin. Despite the very favourable lipid changes obtained in the torcetrapib arm (a 
72% increase in HDL-cholesterol and a 25% decrease in LDL-cholesterol), the rate of major 
cardiovascular events was increased by 25% and the deaths from cardiovascular causes by 
40%; all-cause mortality was increased by 58% and an increase in blood pressure and 
aldosterone levels, therefore unrelated to CETP inhibition, was also observed in the active 
arm. Whereas the pressor and aldosterone-stimulating effects could explain the 
cardiovascular results, it was harder to understand the increased rate of deaths from 
noncardiovascular  causes induced by torcetrapib: the increase was due to more deaths from 
cancers and infections. Since CETP inhibition alters the size and the composition of the HDL 
particles (Barter & Kastelein, 2006), these qualitative changes could predispose to an 
increased susceptibility to neoplasms and infections.  
These negative results did not stop the development of other drugs of the same class: very 
recently the safety of anacetrapib was positively evaluated in the DEFINE study (Cannon et 
al., 2010) and the increased HDL particles exhibited a strong ability to suppress macrophage 
toll-like receptor 4-mediated inflammatory responses (Yvan-Charlet et al., 2010). A more 
direct way to stimulate the reverse cholesterol transport is the infusion of reconstituted HDL 
or Apo A-I mimetic peptides: with both therapeutic approaches a potent anti-inflammatory 
effect was observed (Natarajan et al., 2010).  
4. Anti-platelet agents 
Atherosclerotic thrombotic events are always characterized by an important inflammatory 
activation which is a consequence of the release of chemokines and cytokines from the 
platelets (Gurbel et al., 2009); however platelets are also involved in the initiation and the 
early progression of atherosclerosis mediating leukocyte recruitment and adhesion to the 
vascular wall (Antoniades et al., 2010). Many markers of platelet activation are currently 
investigated: in this context prospective studies and meta-analysis suggest a correlation 
between an increase in mean platelet volume and the risk of thrombosis (Gasparyan et al., 
2011); in addition the soluble form of CD40 ligand has been studied in sera of human 
subjects and seems to have a prognostic role in atherothrombosis (Antoniades et al., 2010). 
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The most used anti-platelet drug, aspirin, is able to decrease serum CRP and patients with 
the highest baseline CRP levels derives the greatest benefit from this drug.  
Trials of cardiovascular prevention with aspirin do not always confirm the positive effects of 
an anti-thrombotic approach, at least in the primary setting: also recently updated 
guidelines suggest judicious use of anti-platelet drug (Bell et al., 2011). The limited 
protective effects of aspirin have led to the concept of aspirin resistance (Gasparyan et al., 
2008).           
5. Phospholipase A2 and ACAT inhibitors 
In atherosclerosis the interactions between lipoprotein metabolism and inflammation are 
modulated by the complex phospholipase A2 (PLA2) superfamily. This family comprises 
five types of enzymes, of which the secretory PLA2 (sPLA2) and the lipoprotein-associated 
PLA2 (Lp-PLA2) have been associated with atherogenesis (Garcia-Garcia & Serruys, 2009). 
These enzymes catalyze the hydrolysis of the centre (sn-2) ester bond of phospholipids to 
produce non-esterified fatty acids (in particular arachidonic acid) and lysophospholipids 
(lysophosphatidylcholine): the atherogenic consequences are the formation of smaller and 
denser HDL and LDL particles, the formation of vascular LDL aggregates, the increased 
LDL oxidation, the synthesis of potent inflammatory lipid mediators such as prostaglandins 
and leukotrienes (Rosenson, 2009). Therefore inhibitors of the types of PLA2 have been 
developed and have reached the phase III clinical evaluation, one for LpPLA2 (darapladib) 
and one for sPLA2 (varespladib). 
In human studies darapladib  induced a small but significant decrease in the inflammatory 
markers hsCRP and interleukin-6 with no changes in plasma lipid levels. In the IBIS-2 trial 
after 12 months the drug did not affect the primary end point, coronary plaque volume 
evaluated by intravascular ultrasound (IVUS); however necrotic core size remained 
unchanged in the active arm but increased in those treated with placebo (Boekholdt et al., 
2008). Darapladib is now being evaluated in two large placebo-controlled cardiovascular 
outcome studies – STABILITY and SOLID-TIMI 52. As for varespladib, in the PLASMA 
Phase II the drug was demonstrated to induce a decrease in both oxidized LDL and CRP; an 
ongoing Phase III cardiovascular outcome study (VISTA-16) have recruited high risk 
patients.  
Another important enzyme involved in the cellular cholesterol metabolism is acyl-coenzyme 
A:cholesterol acyltransferase (ACAT): this protein is able to catalyse cholesteryl ester 
formation by transfer of fatty acyl chain from acyl-coenzyme A to cholesterol. Two isozymes 
are present, one expressed in macrophages in atherosclerotic lesions (ACAT-1) and the other 
mainly expressed in small intestine (ACAT-2): therefore nonselective pharmacological 
inhibition of ACAT was expected to exert a double favourable effect, suppressing both foam 
cell formation in arterial walls and cholesterol intestinal absorption. Unfortunately results of 
the studies in human subjects were disappointing: avasimibe and pactimibe, the two 
nonselective ACAT inhibitors developed for clinical use, gave null or negative results (Fazio 
& Linton, 2006). Very recently a potent and selective ACAT-1 inhibitor, K-604, with 
significant anti-atherosclerotic effects in vitro and in experimental animals, entered a Phase II 
trial (Yoshinaka et al., 2010).  
www.intechopen.com
 
Cardiovascular Risk Factors 
 
310 
6. Leukotriene pathway inhibitors 
Leukotrienes (LTs) belong to the family of eicosanoids and exert potent pro-inflammatory 
smooth muscle constrictive actions. It is well known their involvement in many 
inflammatory and allergic diseases, such as rheumatoid arthritis, inflammatory bowel 
disease, and bronchial asthma. Initially a leukotriene receptor blocker, i.e. montelukast, was 
administered to acute coronary syndrome patients to evaluate the endothelial function in 
brachial artery (clinicaltrials.gov NCT00351364, data unpublished). Subsequently inhibitors 
of both 5-lipoxygenase (5-LO) (atreleuton) and 5-lipoxygenase activating protein (FLAP) 
(veliflapon) were studied in human subjects. Atreleuton, a potent 5-LO inhibitor, was 
administered in acute coronary syndrome patients for 24 weeks and was able to reduce both 
the appearance of new coronary plaques and the volume of noncalcified plaques in 
comparison with placebo; these effects were paralleled by a 66% reduction of hsCRP (Tardif 
et al., 2010). Instead veliflapon, a weak FLAP inhibitor, induced a decrease in LTB4 
production and myeloperoxidase activity with a nonsignificant reduction in CRP 
(Hakonarson et al., 2005).  
7. CCR2 blockade 
One of the main players in the inflammatory cascade induced by the atherosclerotic changes 
is chemokine CC motif ligand 2 (CCL2), also known as monocyte chemoattractant protein-1: 
this chemokine, through the interaction with its receptor chemokine receptor 2 (CCR2), 
efficiently induces the recruitment of circulating blood monocytes to become plaque 
macrophages. Very recently MLN1202, a highly specific humanized monoclonal antibody 
that recognizes CCR2 and inhibits CCL2 binding, was evaluated in a randomized, double-
blind, placebo-controlled trial: the main aim was to measure possible decrease in hsCRP 
with the active treatment in cardiovascular high-risk patients (Gilbert et al., 2011). The 
results of this preliminary study confirmed a significant 26% reduction in the inflammatory 
marker, but obviously we need to perform outcome studies in order to establish a role of 
this new therapeutic approach in the treatment of atherosclerosis.  
8. Peroxisome Proliferator-Activated Receptor (PPAR) agonists and 
Polyunsaturated Fatty Acids (PUFAs)    
PPARs are ligand-activated transcription factors belonging to the nuclear receptor 
superfamily (Oyekan, 2011). Through cellular mechanisms called transactivation, binding of 
PPAR/nuclear retinoid receptor (RXR) heterodimers to PPAR response elements (PPREs) in 
the promoter region of target genes, and transrepression, interference with transcription 
factors such as nuclear factor-kB (NF-kB) and activator protein-1 (AP-1), these transcription 
factors exert multiple and complex effects involving the regulation of the vascular tone, 
inflammation and metabolism. The PPAR family consists of three isoforms, ǂ, Ǆ, and ǃ/ǅ, 
which possess distinct functions, with corresponding agonists. 
PPAR-ǂ agonists (fibric acid derivatives = fibrates) have demonstrated potentially very 
favourable effects on serum lipids with a significant decrease in triglyceride levels and more 
modest effects on LDL-cholesterol (a decrease) and HDL-cholesterol (an increase); in 
addition LDL size is modified with a decrease of more atherogenic small dense particles. All 
these positive changes are theoretically complementary to those induced by statins 
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(Abourbih et al., 2009) and are paralleled by a significant anti-inflammatory modulation, as 
demonstrated both in vitro and in vivo (Adameova et al., 2009). Despite these considerations 
and the long time of clinical evaluation (more than 30 years in Europe), considerable 
controversy still remains about therapeutic efficacy, also after recent reevaluation (Jun et al., 
2010; Goldfine et al., 2011).  
The same negative results were observed in the ACCORD-Lipid substudy which compared 
a statin monotherapy with a combination therapy with a statin  + a fibrate in type 2 diabetic 
patients, who are the population with the theoretical maximal advantage from the 
combination (Ginsberg et al., 2010). However a prespecified analysis showed a 31% 
reduction in the primary end point (nonfatal MI, nonfatal stroke, or death from 
cardiovascular causes) in the subgroup of patients with the most negative metabolic profile 
(baseline triglyceride levels >204 mg/dl and HDL-cholesterol levels <34 mg/dl). 
PPAR-Ǆ agonists (thiazolidinediones = glitazones) was known as anti-inflammatory agents for 
a long time (Duan et al., 2009): two molecules are available for administration in humans, 
pioglitazone and rosiglitazone. They have a specific therapeutic indication for type 2 diabetes 
mellitus due to their improvement in insulin sensitivity, supporting the interpretation of type 2 
diabetes mellitus as an auto-inflammatory disease (Dinarello, 2010; N. Wang et al., 2011). In 
vitro, in human blood monocytes, pioglitazone reduces synthesis of IL-1ǃ, tumor necrosis 
factor (TNF)-ǂ, IL-6, MCP-1, Toll-like receptors (TLRs) (Dasu et al., 2009). Also in vivo, in 
human subjects, pioglitazone exerts potent anti-inflammatory effects with a significant 
decrease in hsCRP levels in both diabetic and nondiabetic individuals (Pfützner et al., 2010). 
Like fibrates, cardiovascular end points evaluated in large randomized studies with glitazones 
gave disappointing results. The only published outcome trial with this group of drugs is the 
PROactive trial (Dormandy et al., 2005): in this study pioglitazone induced a nonsignificant 
reduction in the primary end point (a composite of death, nonfatal MI, stroke, major leg 
amputation, acute coronary syndrome, and coronary or leg revascularization); however the 
principal secondary end point (a composite of all-cause death, nonfatal MI, and stroke) was 
significantly reduced by 16%. On the contrary in different trials rosiglitazone gave some 
suspicions about detrimental effects on cardiovascular events: a large meta-analysis concluded 
that this drug may increase the risk of cardiovascular events (MI, death) (Nissen & Wolski, 
2007), possibly through a more favourable effect of pioglitazone on the lipid profile (Goldberg 
et al., 2005). A possible step forward in the development of PPARs is the evaluation of a dual 
ǂ/Ǆ agonist: after the withdrawal of muraglitazar and tesaglitazar for important toxicities, 
aleglitazar is currently being investigated in type 2 diabetic patients (Paras et al., 2010). 
Other drugs which are able to decrease triglyceride levels are omega-3 fatty acids: the 
attempt to copy Eskimo diet was successful in the secondary prevention of cardiovascular 
diseases with important complex anti-inflammatory effects, which probably involve the 
above mentioned mediators resolvins (De Caterina, 2011). 
9. Succinobucol and fasudil 
Another possible target for atherosclerosis treatment is represented by the blockade of the 
oxidative stress, and in particular of the oxidation of lipoproteins (Libby et al., 2011): this 
was the reason why anti-oxidant vitamins (vitamin C and E) were evaluated in randomized 
controlled trials, unfortunately with no success (Kris-Etherton et al., 2004). Two drugs exert 
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similar potent in vitro anti-oxidant effects and have been studied in atherosclerotic patients: 
succinobucol and fasudil. Succinobucol is a derivative of probucol, previously withdrawn at 
Phase III evaluation for safety concerns, with well-demonstrated anti-inflammatory and 
anti-oxidant effects in endothelial and blood mononuclear cells (Kunsch et al., 2004). The 
ARISE trial recently examined the effects of succinobucol  on cardiovascular events in 
patients with a recent acute coronary syndrome: there was no significant difference in the 
primary end point (cardiovascular death, resuscitated cardiac arrest, MI, stroke, unstable 
angina, or coronary revascularization); the composite secondary end point of cardiovascular 
death, MI, cardiac arrest and stroke was 19% lower in the succinobucol arm compared to 
placebo and reached statistical significance (Tardif et al., 2008). Another interesting 
observation of the study, tertiary end point, was the 63% relative reduction in the onset of 
new diabetes, related to a reduction in glycosilated haemoglobin in diabetic patients.  
Fasudil is an inhibitor of Rho-kinase, an important downstream effector of the small GTP-
binding protein RhoA (Satoh et al., 2011). It has been demonstrated that the RhoA/Rho-
kinase pathway exerts a specific role in the pathogenesis of vasospasm, atherosclerosis, 
ischemia-reperfusion injury, hypertension, stroke, and heart failure. Fasudil is already 
marketed in Japan for the acute treatment of cerebral vasospasm but the possible additional 
indications in human subjects are not completely established (Zhou et al., 2011). 
10. Anti-hypertensive drugs 
Despite intensive research the pathogenesis of hypertension, the leading risk factor of death 
in the entire world (Ezzati et al., 2002), remains elusive. The hypothesis of a low-grade 
inflammatory activation could explain many aspects of the hypertensive process and 
therefore is actively investigated (Harrison et al., 2011;  Leibowitz & Schiffrin, 2011; 
Montecucco et al., 2011). If we can translate these observation to the clinical ground, the 
therapeutic strategies should keep account of possible anti-inflammatory modulations of the 
hypotensive drugs adding more fuel to the controversy about the protective role exerted by 
the blood pressure reduction per se or the presence of additional pleiotropic actions of some 
classes of drugs with respect to others: “outcomes beyond blood pressure control?” (Sever et 
al., 2006; Staessen et al., 2010). In this context the renin-angiotensin system inhibitors 
(angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, renin 
inhibitors) could be the best choice since the fundamental role of this system in the 
activation of the vascular inflammation is widely demonstrated (Marchesi et al., 2008): this 
is confirmed by the in vivo demonstration of a significant decrease of various inflammatory 
markers induced by these drugs (reviewed in Montecucco et al., 2009).  
However, the most comprehensive guidelines for the treatment of hypertension do not 
consider an inflammation-based approach: on the contrary the updated versions of the 
European Society of Hypertension/European Society of Cardiology guidelines did not 
confirm the role of CRP as a cardiovascular risk factor for the prognostic stratification, as 
proposed in the first edition (Mancia et al., 2007). All the hypertension guidelines emphasize 
the control of blood pressure levels as the main target for the therapeutic choices, without a 
classification of the different available drugs and suggesting that frequently we need to 
prefer a drug combination to improve effectiveness and limit side effects. In terms of the 
atherosclerotic process a partial confirmation of this approach comes from the IVUS 
substudy of the CAMELOT trial which demonstrated a significant slowing in the 
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progression of the atheroma volume with a calcium-antagonist (amlodipine, a potent and 
possibly more effective hypotensive drug) compared to an angiotensin-converting enzyme 
inhibitor (enalapril) (Nissen et al., 2004).  
11. Immunosuppressive agents 
In this section we will discuss the anti-atherosclerotic effects of drugs developed for 
immunosuppression and therefore without a primary metabolic action. In terms of 
immunosuppression nothing is more powerful and studied than corticosteroids (Rhen & 
Cidlowski, 2005). 35 years ago corticosteroid administration was shown to exert deleterious 
effects in patients with MI (Roberts et al., 1976); however very recently oral prednisone was 
used successfully to prevent restenosis after PCI with bare metal stents in comparison with 
bare metal stents alone(better event-free survival) and drug-eluting stents (similar outcome) 
(Ribichini et al., 2011). 
As discussed in the introduction, a proof-of-concept for the role of inflammation in the 
atherosclerotic process would be a clinical trial with well tolerated anti-inflammatory drugs, 
devoid of metabolic effects: methotrexate and canakinumab could be good choices and have 
been proposed recently. 
For other drugs the tolerability in uncomplicated atherosclerotic subjects could be more 
problematic with a disadvantageous risk-benefit ratio, but their potentially positive 
cardiovascular effects in patients with a specific immunosuppressive indication can be 
carefully monitored in clinical trials for post hoc analysis (Westlake et al., 2010). Another 
possible application is the administration of these drugs for a limited period of time (e.g. for 
a few days after PCI). 
TNF-ǂ antagonists are extensively used in autoimmune diseases with a significant 
cardiovascular protection (Tracey et al., 2008), possibly related to the pivotal role of this 
cytokine in vascular dysfunction: recently, in a population of subjects who underwent 
carotid endarterectomy for a significant stenosis, we found an increase in TNF-ǂ plasma 
levels in symptomatic patients for an ischemic cerebrovascular event with respect to 
asymptomatic patients (Montecucco et al., 2010). TNF-ǂ antagonists have been evaluated in 
vascular disorders accompanying chronic disordes (Crohn’ s disease and rheumatoid 
arthritis) with the demonstration of improvement in endothelial function (Schinzari et al., 
2008; Hürlimann et al., 2002). In addition to the anti-inflammatory effects, these drugs also 
induce a favourable lipid profile with an increase in HDL-cholesterol and apolipoprotein A-
I (van Eijk et al., 2009).  
IL-1 seems to exert a central role in the intense inflammatory response which follows a MI. 
Using a recombinant form of the naturally occurring antagonist (anakinra), a pilot study 
was recently performed to test the safety and effects of this drug on post-MI left ventricular 
remodelling and CRP serum levels (Abbate et al., 2010). Anakinra was able to mitigate 
significantly left ventricular remodelling, evaluated  with both cardiac magnetic resonance 
and echocardiography, and the changes in CRP levels correlated with the changes in cardiac 
anatomy. 
Another new important inflammatory pathway involves p38 mitogen-activated protein 
kinase (MAPK). This phosphorylation cascade can be activated by a vascular injury, such as 
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coronary stenting with subsequent neointimal proliferation and in-stent restenosis 
(Schieven, 2005), and represents an important intracellular switch for the production of key 
inflammatory cytokines (IL-1ǃ, TNF-ǂ, and IL-6), inflammatory enzyme cyclooxygenase-2 
and matrix metalloproteases. Recently a p38 MAPK inhibitor (dilmapimod, SB-681323) has 
been shown to significantly attenuate the inflammatory activation induced by a PCI 
procedure with positive consequences in post-procedural outcomes (Sarov-Blat et al., 2010).  
Interesting observations came from the administration of the immunosuppressive drug 
mycophenolate mofetil in atherosclerotic patients for a limited period of time: the drug, 
devoid of effects on both serum lipids and blood pressure, was able to attenuate cellular and 
biochemical inflammatory activation in the unstable carotid plaques of patients who 
subsequently underwent endarterectomy for advanced stenosis (van Leuven et al., 2006; 
Van Leuven et al., 2010). At the very beginning of  the clinical evaluation are the inhibitors 
of Toll-like receptors, involved in the innate immune response (Hennessy et al., 2010; Cole & 
Monaco, 2010).   
12. Conclusion 
Recently the title of an editorial in Circulation was “Could direct inhibition of inflammation 
be the next big thing in treating atherosclerosis?” (Natarajan & Cannon, 2010). This is 
certainly a fascinating strategy because it tries to exert a fully pathogenetic approach, 
though we need not to forget the frustrations, caused by so many disappointing results. In 
this context we know that it is not always wise to found our evaluation on surrogate end 
points: only randomized controlled trials with cardiovascular hard end points can give the 
final answer.  
     
Take-home messages 
- Lifestyle choices are an essential part of the cardiovascular prevention and physicians 
must exert every effort to obtain a good compliance from patients 
- In terms of therapeutic control of the different risk factors physicians must reach better
results 
- At the present time physicians have to focus at the single risk factors with the awareness 
that the inflammatory activation is important for the atherosclerotic process 
- hsCRP represents a useful marker of inflammation and an excellent support for the
prognostic stratification   
- Additional help can derive from carotid US and coronary calcium score 
- In the context of blockade of the inflammatory activation statins and RAS-inhibitors offer 
good choices in terms of safety and effectiveness 
- Specific ant-inflammatory drugs need to be carefully evaluated with appropriate trials 
- At the present time these drugs may be useful for a limited period of time (e.g.: after a
PCI) 
- Intense investigation on this topic will certainly suggest new therapeutic targets and
strategies 
In this review we tried to give an update of the experimental and clinical data with already 
marketed drugs or with Phase III therapeutic principles but we did not discuss the possible 
use of an immunomodulating (not immunosuppressive) approach: expansion of regulatory 
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T cells, a subset of T lymphocytes with a well demonstrated anti-inflammatory role, and 
atherosclerosis-specific immunization are thought as promising therapeutic opportunities 
and are actively investigated (Klingerberg & Hansson, 2009; van Puijvelde et al., 2008). 
Although at the present time the physicians are confident with the use of drugs developed 
for particular aspects of the atherosclerotic spectrum (decrease of blood pressure, decrease 
in LDL-cholesterol, increase in HDL-cholesterol, decrease in glucose, etc.),  the “unfinished 
business” of cardiovascular prevention (Libby, 2005) drives our efforts to find new targets 
and strategies against the pernicious activation of inflammation in atherosclerosis.  
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